Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119938) titled 'Tolerability and Safety of Vericiguat Initiation at 10 mg vs 5 mg in Patients with HFrEF and SBP>=130 mmHg:A Randomized Trial' on March 5.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Hospital of Jilin University
Condition:
Heart failure
Intervention:
Treatment group:vericiguat 10mg q.d po
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-03-06
Target Sample Size: Treatment group:70;Control group :70;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=311407
Published by HT Digital Conte...